Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Polly Chuntova"'
Autor:
Naozumi Harada, Akane Yamamichi, Kazunari Akiyoshi, Polly Chuntova, Hiroshi Shiku, Hideho Okada, Tiffany A Chen, Bunta Kakihara, David Diebold
Publikováno v:
Neuro Oncol
We have identified a novel HLA-A*02:01-restricted CD8 T-cell epitope encompassing the H3.3K27M mutation and a corresponding high-affinity T-cell receptor (TCR) that recognizes the epitope. While the development of adoptive cell transfer therapy using
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87b16b3848ded20ecbf3633a64434a50
https://europepmc.org/articles/PMC8598662/
https://europepmc.org/articles/PMC8598662/
Autor:
Noriyuki Kasahara, Manish K. Aghi, Alexander F Haddad, Megan Montoya, Polly Chuntova, Sara Collins, Jordan Spatz, Jacob S. Young, Sabraj Gill, Elaina Wang
Publikováno v:
Neuro-Oncology. 23:vi166-vi166
Glioblastoma (GBM) leads to severe systemic and local immunosuppression, and immunotherapies have had limited clinical success. Here, we evaluated the treatment efficacy of RLI, a superagonist of T-cell activator IL-15, delivered to tumor cells using
Autor:
Sebastien Ronseaux, Kira Downey, Brandon Nicolay, Rohini Narayanaswamy, Megan Montoya, Christine Hudson, Hideho Okada, Polly Chuntova
Publikováno v:
Neuro Oncol
Recent studies have demonstrated the impacts of 2-HG on the anti-tumor immune response in isocitrate dehydrogenase (IDH)-mutant gliomas. Our laboratory has reported that mutant IDH1 (IDH1R132H) suppresses STAT1, the master regulator of IFN-responses
Publikováno v:
Neuro Oncol
Despite the recent successes in cancer immunotherapy, brain tumors continue to present a significant challenge due to the unique relationship between the CNS and the immune system. Adoptive cell transfer of chimeric antigen receptor T-cells (CAR-T ce
Autor:
Joseph H Garcia, Fara Dayani, Ankush Chandra, Soumya Sagar, Manish K. Aghi, Jonathan Rick, Saman Arfaie, Polly Chuntova, Darryl Lau, Cecilia L Dalle Ore, Garima Yagnik, Angel Ordaz, Alan Nguyen
INTRODUCTION: Glioblastoma is an aggressive cancer with a dismal median survival of under two years. Recent studies have shifted the paradigm of glioblastoma from a homogenous mass of tumor cells into a complex organ containing interacting elements.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a487e6064efaf9ecb941cea7062bfdc
https://europepmc.org/articles/PMC6217110/
https://europepmc.org/articles/PMC6217110/
Autor:
Megan Montoya, Alexander F Haddad, Jacob S. Young, Polly Chuntova, Manish K. Aghi, Sara Collins, Matheus P. Pereira, Sabraj Gill, Jordan Spatz, Noriyuki Kasahara, Nikhil V. Mummaneni
Publikováno v:
Neuro Oncol
BACKGROUND Severe local and systemic immune suppression in glioblastoma (GBM) contributes to the failure of single-agent immunotherapies in clinical trials. In this study, we evaluated the efficacy of locally delivered combination immunotherapy in a
Publikováno v:
Expert review of endocrinologymetabolism. 8(4)
Fibroblast growth factor receptor (FGFR) signaling is a vital component of both embryonic and postnatal mammary gland development, which has prompted researchers to investigate both its relevance to breast cancer and its potential as a therapeutic ta
Publikováno v:
Molecular Cancer Research. 14:B68-B68
Inflammation has long been recognized as a possible trigger that contributes to tumor initiation. Numerous studies have shown that cells of both the innate and adaptive immune systems are able to support tumor formation and growth through secretion o
Publikováno v:
Molecular Cancer Research. 11:B107-B107
Aberrant activation of fibroblast growth factor receptors (FGFRs) has been linked to breast cancer growth and progression. FGFR activation in tumor cells acts through both autocrine and paracrine mechanisms to contribute to tumor growth. Our previous